DAIC

FEBRUARY 6, 2024

Matthew Segar co-authored a study in JACC Heart Failure led by his research and residency mentor, University of Texas Southwestern Medical Center's Dr. Ambarish Pandey , that utilized a machine learning-based-approach to identify, understand, and predict diuretic responsiveness in patients with acute decompensated heart failure (ADHF).

Heart Failure 111

Heart Failure Research Hospital Cardiovascular Disease 111

DAIC

JANUARY 5, 2024

As the Diagnostic and Interventional Cardiology (DAIC) team welcomes in the New Year, we also have taken a few moments to reflect back on the Top 10 most read content from 2023. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study

Atrial Fibrillation 105

Atrial Fibrillation Aortic valve Cardiothoracic Interventional Cardiology 105

DAIC

FEBRUARY 12, 2024

Barostim is the world’s first FDA-approved neuromodulation heart failure device, which works by stimulating baroreceptors — natural sensors located in the wall of the carotid artery, according to CVRx. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Heart Failure 104

Heart Failure Hospital Quality of Life Heart Attack 104

DAIC

MAY 6, 2024

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

DAIC

FEBRUARY 15, 2024

(AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF). It is estimated that 26 million worldwide are living with congestive heart failure.

Heart Failure 89

Heart Failure Cardiomyopathy Quality of Life Innovation 89

The British Journal of Cardiology

FEBRUARY 20, 2024

Multidisciplinary experts in heart failure care from across the UK and wider afield gathered for the recent 26th British Society of Heart Failure (BSH) annual meeting. Dr Aaron Henry reports highlights from the meeting.

Heart Failure 69

Heart Failure Technology Arrhythmia Obesity 69

DAIC

DECEMBER 19, 2023

Getty Images milla1cf Tue, 12/19/2023 - 18:09 December 19, 2023 — BioCardia, Inc. , Getty Images milla1cf Tue, 12/19/2023 - 18:09 December 19, 2023 — BioCardia, Inc. , This study follows BioCardia’s three previous co-sponsored clinical trials with MSCs in ischemic heart failure: TACHFT 1 , POSEIDON 2 and TRIDENT 3.

Heart Failure 105

Heart Failure Interventional Cardiology Pulmonary Heart Disease 105

American College of Cardiology

DECEMBER 14, 2023

Bailey MD, FACC, discuss the Top Takeaways from 2023 in Heart Failure. In this interview, Clyde Yancy MD, MSc, FACC, and Alison L.

Heart Failure 54

Heart Failure Article 54

Frontiers in Cardiovascular Medicine

JANUARY 31, 2025

IntroductionVentricular assist devices (VADs) are lifesavers for people with advanced heart failure. The design of these devices has undergone drastic changes over time with the latest designs being far more efficient, small, lightweight, and more user-friendly.

Document 80

Document Innovation Heart Failure Technology 80

Clinical Trial Results

DECEMBER 21, 2023

Disclosures: TBD

Heart Failure 76

Heart Failure 76

CardiacWire

OCTOBER 6, 2024

The original FINEARTS-HF trial presented at ESC 2024 saw finerenone drive a 16% reduction in cardiovascular death and HF events over 32 months, while the new analysis suggests that finerenone’s benefits are greatest if started shortly after patients experience a worsening heart failure event. in the future.

Heart Failure 59

Heart Failure Blood Pressure Kidney Disease Diabetes 59

Cardiovascular Diabetology

AUGUST 11, 2024

We evaluated the prevalence of “heart stress” (HS) based on NT-proBNP cut-points proposed by the 2023 Consensus of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in asymptomati.

Blood Pressure 111

Blood Pressure Heart Failure Hypertension Diabetes 111

The British Journal of Cardiology

JUNE 11, 2024

In this article we focus on areas of the European Society for Cardiology (ESC) heart failure guideline 2023 update that will be most relevant in the day-to-day management of patients with heart failure.

Heart Failure 40

Heart Failure Article Outcomes 40

Frontiers in Cardiovascular Medicine

MARCH 30, 2025

Infection (75.47%, 160/212) and heart failure (51.42%, 109/212) were common comorbidities. Demographic, clinical, and diagnostic data, as well as follow-up outcomes, were reviewed. In-hospital mortality was 5.19% (11/212), with follow-up mortality of 20.28% (43/212).

Risk Factors 52

Risk Factors Pediatrics Cardiomyopathy Pulmonary 52

European Journal of Heart Failure

JANUARY 12, 2024

Abstract Background Existing data on the association between blood pressure levels and adverse cardiovascular outcomes in patients with heart failure (HF) are inconsistent. Methods A systematic review and meta-analysis were conducted using MEDLINE, Embase, the Cochrane Library, and Web of Science databases up to 5 May 2023.

Blood Pressure 81

Blood Pressure Heart Failure Outcomes Cardiovascular Disease 81

American College of Cardiology

FEBRUARY 5, 2024

Hypertension represents a major modifiable risk factor for coronary artery disease (CAD), heart failure (HF), stroke, chronic kidney disease (CKD), and dementia.

Hypertension 75

Hypertension Coronary Artery Disease Kidney Disease Dementia 75

European Journal of Heart Failure

FEBRUARY 5, 2025

Methods and results TRED-HF was a randomized trial investigating heart failure therapy withdrawal in patients with recovered DCM over 6months. Participants were recommended to restart therapy post-trial and were followed until May 2023. Those randomized to continue therapy subsequently withdrew treatment between 6 and 12months.

Heart Failure 67

Heart Failure Cardiomyopathy Atrial Fibrillation Arrhythmia 67

Frontiers in Cardiovascular Medicine

FEBRUARY 13, 2024

Heart failure (HF) is recognized as an epidemic in the contemporary world, impacting around 1%–2% of the adult population and affecting around 6 million Americans. billion in 2023, warranting a better understanding of the mechanisms involved in HF. HF remains a major cause of mortality, morbidity, and poor quality of life.

Heart Failure 64

Heart Failure Electrophysiology Quality of Life Arrhythmia 64

Journal of the American Heart Association

MARCH 7, 2025

Mitral transcatheter edgetoedge repair could alter patient management.Methods and ResultsWe systematically reviewed PubMed/Medline, Scopus, and Cochrane Library until January 2023, including studies assessing transcatheter edgetoedge repair in patients with severe mitral regurgitation and cardiogenic shock.

Cardiogenic Shock 45

Cardiogenic Shock Bicuspid/Mitral Myocardial Infarction Heart Failure 45

Medical Xpress - Cardiology

NOVEMBER 26, 2024

From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heart failure and a left ventricular ejection fraction (LVEF) greater than 40 percent, according to a study published online Nov. 16 to 18 in Chicago.

Heart Failure 52

Heart Failure 52

Cardiology Update

NOVEMBER 17, 2023

The Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference took place at the Moscone Center in San Francisco, USA from October 23 – 26, 2023. Dr. Chadi Alraies provides an overview of the top highlights from TCT 2023. The post TCT 2023 Highlights appeared first on Cardiology Update.

Research 52

Research Heart Failure Interventional Cardiology General Cardiology 52

European Journal of Heart Failure

JANUARY 3, 2024

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Co-ordinator) (Netherlands), P. Christian Schulze (CPG Review Co-ordinator) (Germany), Elena Arbelo (Spain), Jozef Bartunek (Belgium), Johann Bauersachs (Germany), Michael A.

Heart Failure 65

Heart Failure Document 65

DAIC

DECEMBER 8, 2023

The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy. milla1cf Fri, 12/08/2023 - 08:07 December 8, 2023 — Procyrion, Inc. ,

Technology 113

Technology Heart Failure Heart Transplant Transplant 113

Frontiers in Cardiovascular Medicine

FEBRUARY 20, 2024

Background Exercise training is commonly employed as a efficacious supplementary treatment for individuals suffering from heart failure, but the optimal exercise regimen is still controversial. 41.70), and Minnesota Living with Heart Failure Questionnaire (MD = −4.45, 95% CI for −6.25 to −2.64) compared to MICT.

Heart Failure 64

Heart Failure Exercise Quality of Life Cardiac Function 64

European Journal of Heart Failure

OCTOBER 31, 2023

This 2023 Cochrane review of 60 randomized trials in 8728 heart failure patients, confirms the benefits of participation in exercise-based cardiac rehabilitation (ExCR), including reduced risk of hospitalization and a clinically meaningful improvement in health-related quality of life.

Cardiac Rehabilitation 40

Cardiac Rehabilitation Heart Failure Exercise Quality of Life 40

CardiacWire

NOVEMBER 15, 2023

The AHA 2023 Scientific Sessions are officially complete. Prevention & Detection – Boosted by GLP-1 obesity buzz and the fact that cardiovascular outcome trends have been headed in the wrong direction, AHA 2023 placed a greater focus on prevention. heart failure).

Blood Pressure 52

Blood Pressure AFIB Obesity Heart Failure 52

Cardiology Update

JANUARY 2, 2024

Important Deadlines: Early registration fee: January 9, 2023. Late registration fee: February 8, 2023. Important Deadlines: Abstract and late-breaking clinical trial submission is closed (Deadline: December 7 and October 17, 2023) Fees: Visit the ACC 2024 website for registration options. Hashtag: #ACVC2024 2. Hashtag: #ACC24 3.

Heart Failure 111

Heart Failure Atherosclerosis Cardiovascular Imaging Non-Invasive Cardiology 111

Cardiometabolic Health Congress

NOVEMBER 16, 2023

2-5, 2023, to gain perspective on the latest advances in the management of glomerular disease. Kidney Week 2023 not only served as a platform for the latest news and updates in the field but also marked the final meeting of the year for practitioners in the specialty of nephrology.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

DAIC

APRIL 16, 2024

a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. The manuscript is available online at the European Journal of Heart Failure website.

Heart Failure 104

Heart Failure Quality of Life Transplant Heart Transplant 104

DAIC

MAY 18, 2024

Researchers presented these findings “Late Breaking Clinical Trials and Science – CIEDs: Early Cardiac Resynchronization Therapy for Patients with Moderately Reduced Ejection Fraction and Left Bundle Branch Block” this morning during the May 16-19 meeting of the Heart Rhythm Society , HRS 2024 , being held in Boston, MA. 2023 Oct;29(10):1412.

Heart Failure 52

Heart Failure Heart Rhythm Research Pacemaker 52

European Journal of Heart Failure

FEBRUARY 16, 2025

ADHF-CS, acutely decompensated heart failure-related cardiogenic shock; AMI-CS, acute myocardial infarction-related cardiogenic shock; CI, confidence interval; HR, hazard ratio; MAP, mean arterial pressure; OPP, organ perfusion pressure; SOFA, Sequential Organ Failure Assessment.

Cardiogenic Shock 40

Cardiogenic Shock Outcomes Myocardial Infarction Heart Failure 40

Journal of Cardiovascular Pharmacology

DECEMBER 20, 2023

Background: Midodrine is occasionally used off-label to treat hypotension associated with advanced heart failure. Objectives: We sought to evaluate the effect of midodrine upon the GDMT prescription pattern and clinical outcomes of patients with decompensated systolic heart failure. All rights reserved.

Heart Failure 52

Heart Failure Hospital Outcomes Article 52

Frontiers in Cardiovascular Medicine

FEBRUARY 28, 2024

Objective To compare the efficacy of LBBP and BiVP in patients with heart failure (HF) complicated with CLBBB. Secondary endpoints were all-cause mortality, heart failure hospitalization (HFH), NT-proBNP, paced QRS duration, pacing threshold, and procedural duration. Methods This was a single-center retrospective study.

Heart Failure 64

Heart Failure Physiology Cardiomyopathy Hospital 64

The British Journal of Cardiology

JUNE 11, 2024

Heart failure (HF) is a major cause of morbidity and mortality in older people, and 80% of people with HF are aged over 60 years. The 2023 summit comprised experts from over 45 top health organisations across Europe, Canada and the US. Despite this, HF remains underdetected and undertreated.

Heart Failure 40

Heart Failure Cardiovascular Disease Outcomes Article 40

All About Cardiovascular System and Disorders

OCTOBER 16, 2023

Current Role of Digoxin in Heart Failure as Per Guidelines and DIGIT-HF trial of Digitoxin Use of digoxin in heart failure has come down markedly over the past decades due to concerns of toxicity and availability of more effective medications. Eur Heart J. Erratum in: Eur Heart J. Eur J Heart Fail.

Heart Failure 52

Heart Failure Atrial Fibrillation Document Hospital 52

European Journal of Heart Failure

MARCH 30, 2025

AHF, acute heart failure; CABG, coronary artery bypass graft; CI, confidence interval; CV, cardiovascular; GDMT, guideline-directed medical therapy; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; OR, odds ratio; PCI, percutaneous coronary intervention. The RevascHeart study.

Coronary Artery Bypass Graft 40

Coronary Artery Bypass Graft Heart Failure Outcomes Coronary Artery Disease 40

Frontiers in Cardiovascular Medicine

DECEMBER 17, 2023

Objectives Our study was to evaluate the effect of Qishen Yiqi Dropping Pills(QSYQ) on the prognosis of chronic ischemic heart failure(CIHF) and its safety. Primary indicators included readmission rates, rates of major adverse cardiovascular events (MACE), and all-cause mortality rates.

Heart Failure 64

Heart Failure Quality of Life Cardiac Function Exercise 64